

**ERVK-7 Blocking Peptide (C-Term)**

Synthetic peptide

Catalog # BP22000b

**Specification**

---

**ERVK-7 Blocking Peptide (C-Term) - Product Information**

Primary Accession

[P61567](#)

Other Accession

[Q902F9](#), [Q42043](#), [Q71037](#), [P61565](#), [P61566](#),  
[Q69384](#), [Q902F8](#), [Q9UKH3](#), [P63135](#)**ERVK-7 Blocking Peptide (C-Term) - Additional Information****Other Names**

Endogenous retrovirus group K member 7 Env polyprotein, Envelope polyprotein, HERV-K(III) envelope protein, HERV-K102 envelope protein, HERV-K\_1q22 provirus ancestral Env polyprotein, Surface protein, SU, Transmembrane protein, TM, ERVK-7

**Target/Specificity**

The synthetic peptide sequence is selected from aa 477-491 of HUMAN ERVK-7

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**ERVK-7 Blocking Peptide (C-Term) - Protein Information****Name** ERVK-7**Function**

Retroviral envelope proteins mediate receptor recognition and membrane fusion during early infection. Endogenous envelope proteins may have kept, lost or modified their original function during evolution. TM anchors the envelope heterodimer to the viral membrane through one transmembrane domain. The other hydrophobic domain, called fusion peptide, mediates fusion of the viral membrane with the target cell membrane (By similarity).

**Cellular Location**

Virion.

**Tissue Location**

Expressed in lung, placenta, testis and peripheral blood lymphocytes.

## **ERVK-7 Blocking Peptide (C-Term) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

## **ERVK-7 Blocking Peptide (C-Term) - Images**

## **ERVK-7 Blocking Peptide (C-Term) - Background**

Retroviral envelope proteins mediate receptor recognition and membrane fusion during early infection. Endogenous envelope proteins may have kept, lost or modified their original function during evolution. TM anchors the envelope heterodimer to the viral membrane through one transmembrane domain. The other hydrophobic domain, called fusion peptide, mediates fusion of the viral membrane with the target cell membrane (By similarity).

## **ERVK-7 Blocking Peptide (C-Term) - References**

Barbulescu M.,et al.Curr. Biol. 9:861-868(1999).  
Sugimoto J.,et al.Genomics 72:137-144(2001).  
Wang-Johanning F.,et al.Oncogene 22:1528-1535(2003).